Jump to: Page Content, Site Navigation, Site Search,
You are seeing this message because your web browser does not support basic web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.
BMJ 2004;328:357-358 (14 February), doi:10.1136/bmj.328.7436.357
It works for symptoms but is not good for future health
| The first 150 words of the full text of this article appear below. |
Menopausal symptoms can be grim, and the desire to replace the hormonal "deficit" with exogenous hormones remains strong. Since the 1950s, hormone replacement therapy has been used increasingly,1 while evidence on the risks of unwanted side effects has accumulated. Twenty five years ago, the increased risk of endometrial cancer emerged, resulting in the addition of progestogen. Cohort studies had examined oestrogen alone and indicated important benefits, but, since the 1980s, combined preparations have dominated. Interpretations of the evidence were therefore confused, since whatever effects oestrogen or progestogen have on disease will differ. Eventually, evidence of increased risk of combined therapy on breast cancer, coronary heart disease, stroke, and venous thromboembolism from a randomised trial was reported.2 This trial was stopped early, after an average of five years' follow up among 17 000 women, during which around 40% stopped their trial drugs. The results from the oestrogen alone arm of the
Klim McPherson, visiting professor of public health epidemiology
Nuffield Department of Obstetrics and Gynaecology, Research Institute, Churchill Hospital, Oxford OX3 7BN (klim.mcpherson@obstetrics-gynaecology.oxford.ac.uk)
Read all Rapid Responses
UK medical students have published unreleased government plans to restrict failed asylum seekers' access to medical care